Rcadia Cardiac COR Analyzer I Has Received Clearance for Marketing by the FDA

HAIFA, Israel - January 30, 2007- Rcadia Medical Imaging, Ltd., developer of novel computer-aided diagnostic software has received clearance to begin marketing one of its products, COR Analyzer I.

Rcadia is the developer of novel computer-aided diagnostic software, can help triage patients that present to the emergency room (ER) with chest pain by immediately screening for coronary artery disease (CAD).

In the United States there are more than 5 million patients present to the ER each year with acute chest pain. Current diagnostic modalities do not effectively triage patients with acute chest pain that show normal cardiac enzyme levels and ECGs. Deciding on the appropriate treatment for these patients causes a variety of clinical and work-flow related issues in the ER. On one hand, missing clinically significant CAD can lead to morbidity; on the other hand, misdiagnosing non-significant CAD can lead to further, unnecessary cardiac evaluations.

 "CAD is a major underlying cause for acute chest pain. Adopting CT and Rcadia's software, particularly in ERs, enables ER personnel to quickly rule out CAD as the culprit for chest pain," says Anna Chacko, MD of the Boston University Medical Center in Boston, MA.

Rcadia's computer-aided diagnostic software packages, COR Analyzer I and COR Analyzer II use proprietary image processing algorithms to analyze cardiac CTA studies. One major goal is to determine whether the chest pain was caused by the presence of CAD. Rcadia's software triage process is based on automatic reconstruction and analysis of the CT images.

According to Dr. Chacko, "CT angiography is being rapidly adopted to triage patients in America's ERs. Rcadia's COR Analyzer II can quickly identify and exclude CAD with a high degree of accuracy and thus, it streamlines patient care and prevents unnecessary delays in diagnosis and care."

In a recent pilot study, Rcadia's software packages, COR Analyzer I and COR Analyzer II successfully identified and excluded CAD in 100% of patients in 99% of arteries. "The real benefit of Rcadia's software is the algorithms' High Negative Predictive Value," explains Jeff Mendel, MD of Caritas St. Elizabeth's Hospital in Boston, MA. Dr. Mendel added that the High Negative Predictive Value (or High NPV) is the key to screening by identifying those patients with "true" negative tests that do not have CAD.

Regulatory notice: The COR Analyzer II is an investigational device and is not yet available for sales in the U.S.